Seaport Res Ptn Analysts Lift Earnings Estimates for HIMS

Hims & Hers Health, Inc. (NYSE:HIMS) – Stock analysts at Seaport Res Ptn boosted their Q4 2024 earnings estimates for shares of Hims & Hers Health in a report issued on Monday, November 4th. Seaport Res Ptn analyst A. Kessler now anticipates that the company will post earnings per share of $0.09 for the quarter, up from their prior forecast of $0.07. The consensus estimate for Hims & Hers Health’s current full-year earnings is $0.22 per share. Seaport Res Ptn also issued estimates for Hims & Hers Health’s Q1 2025 earnings at $0.08 EPS, Q2 2025 earnings at $0.12 EPS, Q3 2025 earnings at $0.15 EPS and Q4 2025 earnings at $0.17 EPS.

HIMS has been the topic of several other research reports. Truist Financial increased their target price on Hims & Hers Health from $13.00 to $23.00 and gave the stock a “hold” rating in a report on Thursday, July 18th. Imperial Capital cut shares of Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research report on Friday, August 9th. Needham & Company LLC began coverage on shares of Hims & Hers Health in a research report on Thursday, August 22nd. They set a “buy” rating and a $24.00 target price on the stock. Deutsche Bank Aktiengesellschaft raised their price target on shares of Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a report on Wednesday. Finally, Canaccord Genuity Group upped their price objective on Hims & Hers Health from $24.00 to $28.00 and gave the stock a “buy” rating in a report on Tuesday. Eight investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $21.00.

Hims & Hers Health Price Performance

HIMS stock opened at $23.44 on Wednesday. The business has a fifty day moving average price of $18.22 and a 200 day moving average price of $18.26. Hims & Hers Health has a fifty-two week low of $6.58 and a fifty-two week high of $25.74. The stock has a market capitalization of $5.03 billion, a price-to-earnings ratio of 53.27 and a beta of 1.06.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.26. The company had revenue of $401.56 million during the quarter, compared to analyst estimates of $382.20 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 11.67%. The company’s revenue was up 77.1% on a year-over-year basis. During the same quarter last year, the business posted ($0.04) earnings per share.

Hedge Funds Weigh In On Hims & Hers Health

Several institutional investors and hedge funds have recently modified their holdings of HIMS. Carnegie Investment Counsel acquired a new stake in Hims & Hers Health during the 3rd quarter worth approximately $5,531,000. International Assets Investment Management LLC acquired a new stake in shares of Hims & Hers Health during the third quarter worth $6,790,000. Sei Investments Co. lifted its position in Hims & Hers Health by 206.9% in the 1st quarter. Sei Investments Co. now owns 56,202 shares of the company’s stock valued at $869,000 after acquiring an additional 37,890 shares in the last quarter. Quantbot Technologies LP boosted its stake in Hims & Hers Health by 3,444.9% in the 1st quarter. Quantbot Technologies LP now owns 214,677 shares of the company’s stock worth $3,321,000 after purchasing an additional 208,621 shares during the period. Finally, Healthcare of Ontario Pension Plan Trust Fund increased its holdings in Hims & Hers Health by 164.1% during the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 528,142 shares of the company’s stock worth $10,663,000 after purchasing an additional 328,142 shares in the last quarter. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, insider Soleil Boughton sold 2,339 shares of the company’s stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $16.50, for a total value of $38,593.50. Following the completion of the sale, the insider now directly owns 176,952 shares of the company’s stock, valued at $2,919,708. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, insider Soleil Boughton sold 2,339 shares of the business’s stock in a transaction on Tuesday, September 17th. The shares were sold at an average price of $16.50, for a total value of $38,593.50. Following the completion of the transaction, the insider now owns 176,952 shares of the company’s stock, valued at $2,919,708. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Michael Chi sold 17,304 shares of the firm’s stock in a transaction on Friday, October 25th. The stock was sold at an average price of $22.00, for a total value of $380,688.00. Following the sale, the insider now directly owns 193,980 shares in the company, valued at $4,267,560. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 650,659 shares of company stock valued at $11,712,198 over the last three months. Company insiders own 17.71% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.